Imotil Plus2 mg + 125 mg

Imotil Plus is an over-the-counter combination product used for the symptomatic relief of acute, nonspecific diarrhea that occurs together with gas-related symptoms such as bloating, abdominal pressure, and cramping.

Established/approved uses

• Short-term (up to 2 days) relief of acute, nonspecific diarrhea in adults and children 12 years and older.
• Relief of associated gas symptoms — bloating, abdominal fullness, and pressure — that frequently accompany acute diarrhea.
• Symptomatic management of traveler's diarrhea (uncomplicated, non-bloody, afebrile) in adults.

Not appropriate uses

• Imotil Plus is not intended for chronic or recurrent diarrhea, or for diarrhea caused by invasive bacterial infection, unless directed by a physician.
• It is not an antibiotic and does not treat the underlying infectious cause of diarrhea.

Each dose unit of Loperamide + Simethicone typically contains loperamide hydrochloride (an antidiarrheal agent) combined with simethicone (an antiflatulent/antifoaming agent). Common OTC strengths include loperamide HCl 2 mg with simethicone 125 mg per caplet/tablet, though exact strengths vary by manufacturer and market.

Imotil Plus is a fixed-dose combination medicine that pairs an antidiarrheal (loperamide) with an antiflatulent (simethicone) to address two of the most common and bothersome symptoms of acute diarrhea at the same time: frequent loose stools and gas-related bloating/cramping.

It is available as an oral caplet or tablet and is intended for short-term, self-limited use in adults and adolescents with acute, nonspecific diarrhea.

Antidiarrheal and antiflatulent combination (Imotil Plus) — combines a gut-motility-reducing antidiarrheal with an antifoaming carminative agent.

Loperamide + Simethicone combines two agents with complementary but distinct mechanisms:

• Loperamide is a peripherally acting opioid-receptor agonist that binds to μ-opioid receptors in the gut wall. It slows intestinal motility and peristalsis, prolongs intestinal transit time, and increases the reabsorption of water and electrolytes, which reduces stool frequency and improves stool consistency. At recommended doses, loperamide does not meaningfully cross the blood-brain barrier and lacks central opioid (analgesic/euphoric) effects.
• Simethicone is an antifoaming agent that lowers the surface tension of gas bubbles trapped within the gastrointestinal mucus, causing them to coalesce so gas can be passed more easily by belching or flatulence. Simethicone is not systemically absorbed and acts locally within the GI lumen.

Together, the components in Loperamide + Simethicone reduce stool frequency/volume while relieving the gas, bloating, and abdominal discomfort that often accompany acute diarrhea.

Imotil Plus is taken by mouth, with or without food. Swallow the caplet/tablet whole with a glass of water. Maintain adequate oral fluid and electrolyte intake (e.g. oral rehydration solution) while using Imotil Plus, as diarrhea can cause dehydration.

The following are well-documented, clinically significant interactions with Imotil Plus (attributable to its loperamide component):

• CYP3A4/P-glycoprotein inhibitors (e.g. quinidine, ritonavir, itraconazole, ketoconazole, gemfibrozil): can increase plasma levels of loperamide, raising the risk of serious cardiac effects (QT prolongation, torsades de pointes, cardiac arrest) — such combinations should be avoided or used only under close medical supervision.
• Other QT-prolonging drugs (e.g. certain antiarrhythmics, antipsychotics, some antibiotics such as macrolides/fluoroquinolones): concurrent use with Imotil Plus may additively increase the risk of QT prolongation and serious arrhythmia, particularly if loperamide is taken above recommended doses.

Simethicone itself has minimal known systemic drug interactions, as it is not absorbed from the gastrointestinal tract.

Imotil Plus is generally well tolerated when used as directed. Reported side effects include:

• Common: constipation, abdominal cramping/pain, nausea, dizziness, dry mouth, flatulence.
• Less common: vomiting, bloating, drowsiness, fatigue.
• Rare but serious: allergic reactions (rash, itching, swelling of the face/lips/tongue, difficulty breathing), abdominal distension, paralytic ileus/toxic megacolon (particularly if used in inappropriate settings, such as active colitis), and serious cardiac rhythm disturbances (see Overdose Effects) — these require immediate medical attention.

Data on the use of Imotil Plus in pregnancy are limited. Imotil Plus should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; a physician should be consulted before use.

Loperamide passes into breast milk in small amounts; simethicone is not absorbed systemically and is not expected to pass into breast milk in clinically significant amounts. As a precaution, breastfeeding women should consult a physician before using Imotil Plus.

• Discontinue Imotil Plus and seek medical care if diarrhea persists beyond 48 hours, if fever develops, or if blood or mucus appears in the stool.
• Do not use Imotil Plus for unexplained or ongoing abdominal pain in the absence of diarrhea.
• Use with caution in patients prone to constipation, as loperamide can cause constipation, abdominal distension, or (rarely) paralytic ileus.
• Taking more than the recommended dose of loperamide (an ingredient of Imotil Plus), or combining it with certain interacting drugs, has been associated with serious cardiac events including QT-interval prolongation, torsades de pointes, and cardiac arrest — never exceed the labeled dose.
• Imotil Plus should be used with caution in patients with hepatic impairment due to reduced drug clearance.
• Maintain adequate fluid and electrolyte replacement while symptoms of diarrhea are present.
• Imotil Plus is not an antibiotic and does not treat infections that may be causing diarrhea.

Overdose of Imotil Plus (primarily due to the loperamide component) can cause central nervous system depression (drowsiness, lethargy, stupor, coordination difficulties, miosis, muscle hypertonia, respiratory depression), urinary retention, and paralytic ileus. Importantly, loperamide overdose or misuse has been associated with serious cardiac events, including QT-interval and QRS-complex prolongation, torsades de pointes, other ventricular arrhythmias, cardiac arrest, and sudden death.

If overdose of Imotil Plus is suspected, seek immediate medical attention or contact a poison control center/emergency services right away. Do not attempt home treatment. Cardiac monitoring and supportive care, including possible use of naloxone for CNS/respiratory depression, may be required in a medical facility.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Imotil Plus is not recommended for self-treatment in children under 12 years of age; safety and efficacy for OTC self-use below this age have not been established. Use in younger children should occur only under direct physician supervision with weight-appropriate dosing.

Elderly

No specific dose adjustment is required for elderly patients based on age alone, but this population may have a higher likelihood of hepatic or renal impairment, so Imotil Plus should be used with routine caution and medical guidance.

Hepatic impairment

Use with caution and physician supervision, as reduced clearance of loperamide may increase systemic exposure and the risk of cardiac and CNS effects (see Precautions and Warnings).

Renal impairment

No well-established dose adjustment is required, but caution and medical advice are recommended in patients with significant renal impairment.

For OTC self-treatment, Imotil Plus should not be used for more than 2 days. If diarrhea persists beyond 48 hours, worsens, or is accompanied by fever or blood/mucus in the stool, discontinue Imotil Plus and seek medical evaluation. Longer-term or recurrent use should only occur under a physician's direction after the underlying cause of diarrhea has been assessed.

Antidiarrheal (peripheral opioid-receptor agonist) combined with an antiflatulent/antifoaming agent.

Loperamide + Simethicone works through two complementary local actions in the gastrointestinal tract: loperamide binds to μ-opioid receptors in the intestinal wall, reducing propulsive peristalsis and increasing transit time so that more water and electrolytes are reabsorbed, which firms up stool and reduces stool frequency; simethicone physically alters the surface tension of gas bubbles within the gut lumen so that small bubbles merge into larger ones that are passed more easily, relieving bloating and gas-related discomfort. Neither component requires systemic absorption to produce its therapeutic effect at the doses used.

Category C (loperamide component; legacy FDA classification) — use only if clearly needed and the potential benefit justifies the potential risk to the fetus.

Imotil Plus is approved for OTC self-use only in individuals 12 years of age and older. Safety and efficacy of self-administered Imotil Plus in children under 12 years have not been established, and the product should not be given to younger children except under a physician's direction with appropriate weight-based dosing of the loperamide component.